BuSpar® (buspirone hydrochloride tablets, USP) is a medication used for the management of anxiety disorders or the short-term relief of anxiety symptoms. Unlike benzodiazepines, barbiturates, or other sedative/anxiolytic drugs, BuSpar is not chemically or pharmacologically related to them. Its mechanism of action involves acting as an agonist of the 5-HT1A receptor. Clinical studies have shown the efficacy of BuSpar in controlling anxiety symptoms in outpatients diagnosed with Generalized Anxiety Disorder (GAD), with many of the patients also experiencing coexisting depressive symptoms. The studies enrolled patients who had been experiencing anxiety symptoms for periods ranging from one month to over one year, with an average duration of six months. BuSpar has been available since 1986, first approved in the United States by Bristol Myers Squibb Co. Click on the image below to begin the exploration journey of Buspirone through the Synapse database!
You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!